Versant Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-828
Closed -$7K 1625
2020
Q3
$7K Buy
828
+406
+96% +$3.86K ﹤0.01% 786
2020
Q2
$3K Buy
422
+47
+13% +$360 ﹤0.01% 1023
2020
Q1
$2K Sell
375
-268
-42% -$2.36K ﹤0.01% 1080
2019
Q4
$7K Sell
643
-71
-10% -$776 ﹤0.01% 856
2019
Q3
$8K Buy
714
+221
+45% +$2.33K ﹤0.01% 820
2019
Q2
$4K Buy
493
+237
+93% +$2.56K ﹤0.01% 1064
2019
Q1
$3K Buy
256
+151
+144% +$2.25K ﹤0.01% 1300
2018
Q4
$1K Sell
105
-13
-11% -$248 ﹤0.01% 1429
2018
Q3
$2K Buy
118
+45
+62% +$1.02K ﹤0.01% 1359
2018
Q2
$1K Hold
73
﹤0.01% 1465
2018
Q1
$1K Buy
+73
New +$1.24K ﹤0.01% 1448
2017
Q4
Sell
-20
Closed 1702
2017
Q3
$0 Buy
20
+7
+54% +$130 ﹤0.01% 1624
2017
Q2
$0 Sell
13
-14
-52% -$277 ﹤0.01% 1593
2017
Q1
$0 Sell
27
-127
-82% -$3.04K ﹤0.01% 1586
2016
Q4
$5K Buy
154
+24
+18% +$717 ﹤0.01% 1039
2016
Q3
$3K Buy
130
+113
+665% +$2.82K ﹤0.01% 1139
2016
Q2
$0 Buy
+17
New +$390 ﹤0.01% 1495

Versant Capital Management's AMAG Position: Q4 2020 in Review

Versant Capital Management sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 828 shares — an estimated $7K sold.

Versant Capital Management first reported a position in AMAG in Q2 2016 and held it in 17 quarters. The position peaked at $8K in Q3 2019. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.

  • Versant Capital Management reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Versant Capital Management sold 828 AMAG Pharmaceuticals shares in Q4 2020, an estimated $7K.
  • Versant Capital Management first reported a position in AMAG Pharmaceuticals in Q2 2016 and held it in 17 quarters.
  • Versant Capital Management's AMAG Pharmaceuticals position peaked at $8K in Q3 2019.
  • 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.

Based on Versant Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.